Japan Hosts $1.2 Billion in API-Related Pharma Projects

---

Researched by Industrial Info Resources (Sugar Land, Texas)--Industrial Info is tracking about 70 capital-spending projects in Japan's Pharmaceutical & Biotech Industry geared toward active pharmaceutical ingredients (API), totaling more than US$1.2 billion in investment value.

The projects include Meiji Seika Pharma Company Limited's (Gifu, Japan) expansion of its penicillin APIs plant in Motosu. Construction is expected to begin in the second quarter of 2024 and wrap up sometime in 2025. Subscribers to Industrial Info's Global Market Intelligence (GMI) Pharmaceutical & Biotech Project Database can click here for more details.

Subscribers can click here for a full list of capital-spending projects for API across Japan, and click here for a list of related plant profiles.

Industrial Info Resources (IIR) is the leading provider of industrial market intelligence. Since 1983, IIR has provided comprehensive research, news and analysis on the industrial process, manufacturing and energy related industries. IIR's Global Market Intelligence (GMI) platform helps companies identify and pursue trends across multiple markets with access to real, qualified and validated plant and project opportunities. Across the world, IIR is tracking more than 200,000 current and future projects worth $17.8 trillion (USD).